Beta Bionics, Inc. (BBNX)
| Market Cap | 454.53M -10.2% |
| Revenue (ttm) | 110.24M +57.9% |
| Net Income | -66.44M |
| EPS | -1.51 |
| Shares Out | 44.56M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 84,351 |
| Open | 9.95 |
| Previous Close | 10.11 |
| Day's Range | 9.70 - 10.22 |
| 52-Week Range | 8.80 - 32.71 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 19.18 (+88.04%) |
| Earnings Date | Apr 21, 2026 |
About BBNX
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which co... [Read more]
Financial Performance
In 2025, Beta Bionics's revenue was $100.25 million, an increase of 53.94% compared to the previous year's $65.12 million. Losses were -$73.20 million, 33.7% more than in 2024.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for BBNX stock is "Buy." The 12-month stock price target is $19.18, which is an increase of 88.04% from the latest price.
News
Beta Bionics price target lowered to $11 from $23 at BofA
BofA analyst Travis Steed lowered the firm’s price target on Beta Bionics (BBNX) to $11 from $23 and keeps a Neutral rating on the shares. After having hosted 34 medtech…
Beta Bionics Touts Pharmacy Push, iLet Momentum and 2027 Mint Patch Pump Plans
Beta Bionics NASDAQ: BBNX Chief Financial Officer Stephen Feider said the company's first-quarter outperformance was supported by increasing use of the pharmacy reimbursement channel, expanded sales c...
Beta Bionics Transcript: Bank of America Global Healthcare Conference 2026
Q1 revenue exceeded expectations due to pharmacy channel growth and field sales expansion. The company is preparing to launch a new patch pump, Mint, by end of 2027, focusing on user experience and manufacturing readiness. Pricing in the pharmacy channel is expected to remain stable due to product differentiation.
Beta Bionics to Present at the Bank of America Securities Health Care Conference
IRVINE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management ...
Beta Bionics price target lowered to $20 from $22 at Stifel
Stifel analyst Jonathan Block lowered the firm’s price target on Beta Bionics (BBNX) to $20 from $22 and keeps a Buy rating on the shares. Q1 results were “relatively solid,”…
Beta Bionics price target lowered to $20 from $32 at Piper Sandler
Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Beta Bionics (BBNX) to $20 from $32 and keeps an Overweight rating on the shares. The firm notes Beta…
Beta Bionics reports Q1 EPS (49c), consensus (45c)
Reports Q1 revenue $27.6M, consensus $26.97M.
Beta Bionics Earnings Call Transcript: Q1 2026
Q1 2026 saw 57% revenue growth to $27.6M, with gross margin expanding to 59.5% and strong pharmacy channel traction. Full-year guidance was raised for revenue, gross margin, and pharmacy mix, while cash reserves remain robust and R&D investments accelerate.
Beta Bionics Earnings release: Q1 2026
Beta Bionics released its Q1 2026 earnings on April 21, 2026, summarizing the period's financial results.
Beta Bionics Slides: Q1 2026
Beta Bionics has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 21, 2026.
Beta Bionics Quarterly report: Q1 2026
Beta Bionics has published its Q1 2026 quarterly earnings report on April 21, 2026.
Beta Bionics sees FY26 revenue $131M-$136M, consensus $132.58M
Sees FY26 gross margin of 57.5% to 59.5%, previously 55.5% to 57.5%. Sees 37% to 39% of new patient starts reimbursed through the PBP channel, previously 36% to 38%. Published…
Beta Bionics Announces First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
IRVINE, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial res...
Beta Bionics price target lowered to $18 from $25 at Truist
Truist lowered the firm’s price target on Beta Bionics (BBNX) to $18 from $25 and keeps a Buy rating on the shares as part of a broader research note previewing…
Beta Bionics, Inc. Investigated by the Portnoy Law Firm
LOS ANGELES, April 14, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Beta Bionics, Inc. (“Beta Bionics" or the "Company") (NASDAQ: BBNX) investors that the firm has initiated an investigation ...
Beta Bionics Proxy statement: Proxy filing
Beta Bionics filed a proxy statement on April 10, 2026, providing details for shareholder voting and corporate governance matters.
Beta Bionics Proxy statement: Proxy filing
Beta Bionics filed a proxy statement on April 10, 2026, providing details for shareholder voting and corporate governance matters.
Beta Bionics to Announce First Quarter 2026 Financial Results on April 21, 2026
IRVINE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to...
Beta Bionics pullback an ‘overreaction,’ says Lake Street
Lake Street believes the pullback in Beta Bionics (BBNX) to be “an overreaction to one metric,” new patient starts, underperforming by about 2% versus consensus expectations in Q4, adding that…
Beta Bionics management to meet virtually with Lake Street
Virtual Meetings to be held March 19-20 hosted by Lake Street.
Beta Bionics Transcript: TD Cowen 46th Annual Health Care Conference
The session highlighted the automation and ease-of-use of the iLet insulin pump, its differentiated business model, and plans for significant sales force expansion. The Mint patch pump is set for late 2027, and a bi-hormonal pump is in phase II trials, aiming to further disrupt the market.
Beta Bionics files automatic mixed securities shelf
17:17 EST Beta Bionics (BBNX) files automatic mixed securities shelf
Beta Bionics to Present at the TD Cowen 46th Annual Health Care Conference
IRVINE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management w...
Beta Bionics price target lowered to $20 from $40 at Lake Street
Lake Street lowered the firm’s price target on Beta Bionics (BBNX) to $20 from $40 and keeps a Buy rating on the shares. The firm, which expects continued investment in…
Beta Bionics price target lowered to $14 from $28 at Baird
Baird lowered the firm’s price target on Beta Bionics (BBNX) to $14 from $28 and keeps a Neutral rating on the shares. The firm updated is model following Q4 results…